GALVUS

This brand name is authorized in Australia, Austria, Brazil, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Lithuania, Mexico, Netherlands, New Zealand, Nigeria, Poland, Romania, Singapore, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug GALVUS contains one active pharmaceutical ingredient (API):

1	Vildagliptin UNII I6B4B2U96P - VILDAGLIPTIN
	Vildagliptin enhances the sensitivity of beta cells to glucose, resulting in improved glucose-dependent insulin secretion by increasing the endogenous levels of these incretin hormones. The administration of vildagliptin results in a rapid and complete inhibition of DPP-4 activity, resulting in increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide).
	Read more about Vildagliptin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
GALVUS Tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A10BH02	Vildagliptin	A Alimentary tract and metabolism → A10 Drugs used in diabetes → A10B Blood glucose lowering drugs, excl. insulins → A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors
Discover more medicines within A10BH02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	3415R
BR	Câmara de Regulação do Mercado de Medicamentos	526528901112315, 526528903115311, 526528904111212
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	649-MEE-0115
EE	Ravimiamet	1316270, 1316281, 1316292, 1316304, 1316315, 1316326, 1316337, 1316348, 1316359, 1316360
ES	Centro de información online de medicamentos de la AEMPS	07414003, 07414005
FI	Lääkealan turvallisuus- ja kehittämiskeskus	108540, 108562
FR	Base de données publique des médicaments	67520378
GB	Medicines & Healthcare Products Regulatory Agency	134117, 196129, 374386, 379881
HK	Department of Health Drug Office	57309, 63165
IE	Health Products Regulatory Authority	71711
IL	מִשְׂרַד הַבְּרִיאוּת	6291
LT	Valstybinė vaistų kontrolės tarnyba	1028704, 1028705, 1028706, 1028707, 1028708, 1028709, 1028710, 1028711, 1028712, 1028713, 1028714, 1028715, 1028716, 1028717, 1028718, 1028719, 1028720, 1056545
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	045M2007
NG	Registered Drug Product Database	A4-5369
Switch country to Nigeria in order to find specific presentations of GALVUS
NL	Z-Index G-Standaard, PRK	85936
NZ	Medicines and Medical Devices Safety Authority	12501
PL	Rejestru Produktów Leczniczych	100179020
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W64467001, W64467002, W64467003, W64467004, W64467005, W64467006, W64467007, W64467008, W64467009, W64467010, W64467011
SG	Health Sciences Authority	13407P
TN	Direction de la Pharmacie et du Médicament	10283291
TR	İlaç ve Tıbbi Cihaz Kurumu	8699504011401, 8699504012163
ZA	Health Products Regulatory Authority	41/21.2/0487